4-(2-Dipropylamino-ethyl)-benzene-1,2-diol

ID: ALA15564

Chembl Id: CHEMBL15564

Cas Number: 66185-61-3

PubChem CID: 3106

Max Phase: Preclinical

Molecular Formula: C14H23NO2

Molecular Weight: 237.34

Molecule Type: Small molecule

Names and Identifiers

Synonyms from Alternative Forms(1): Dipropyldopamine Hydrobromide

Canonical SMILES:  CCCN(CCC)CCc1ccc(O)c(O)c1

Standard InChI:  InChI=1S/C14H23NO2/c1-3-8-15(9-4-2)10-7-12-5-6-13(16)14(17)11-12/h5-6,11,16-17H,3-4,7-10H2,1-2H3

Standard InChI Key:  LMYSNFBROWBKMB-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA15564

   N,N-di-n-propyldopamine

2. Alternative Forms:

   

   ALA15564

   DIPROPYLDOPAMINE HYDROBROMIDE
3. 

   ALA15564

   N,N-di-n-propyldopamine hydrochloride

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 237.34

Molecular Weight (Monoisotopic): 237.1729

AlogP: 2.76

#Rotatable Bonds: 7

Polar Surface Area: 43.70

Molecular Species: BASE

HBA: 3

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 3

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 9.23

CX Basic pKa: 10.47

CX LogP: 2.32

CX LogD: 0.71

Aromatic Rings: 1

Heavy Atoms: 17

QED Weighted: 0.72

Np Likeness Score: -0.18

References

1. Jagoe CT, Kreifels SE, Li J.  (1997)  Covalent binding of catechols to src family SH2 domains,  7  (2): [10.1016/S0960-894X(96)00589-6]

2. Weinstock J, Gaitanopoulos DE, Stringer OD, Franz RG, Hieble JP, Kinter LB, Mann WA, Flaim KE, Gessner G..  (1987)  Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzothiazol-2-one 7-ethylamines.,  30  (7): [PMID:2955118] [10.1021/jm00390a009]

3. Fisher LE, Rosenkranz RP, Clark RD, Muchowski JM, McClelland DL, Michel A, Caroon JM, Galeazzi E, Eglen R, Whiting RL.  (1995)  N,N-6-bis-[2-(3,4-dihydroxybenzyl)pyrrolidinyl]hexane, a potent, selective, orally active dopamine analog with hypotensive and diuretic activity,  5  (20): [10.1016/0960-894X(95)00413-N]

4. Ross ST, Franz RG, Wilson JW, Brenner M, DeMarinis RM, Hieble JP, Sarau HM..  (1986)  Dopamine receptor agonists: 3-allyl-6-chloro-2,3,4,5-tetrahydro- 1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol and a series of related 3-benzazepines.,  29  (5): [PMID:2871192] [10.1021/jm00155a024]

5. Huffman WF, Hall RF, Grant JA, Wilson JW, Hieble JP, Hahn RA..  (1983)  4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a novel class of potent presynaptic dopamine receptor agonists.,  26  (7): [PMID:6306238] [10.1021/jm00361a001]

6. PubChem BioAssay data set, 

7. PubChem BioAssay data set, 

8. Cannon JG, Hsu FL, Long JP, Flynn JR, Costall B, Naylor RJ..  (1978)  Preparation and biological actions of some symmetrically N,N-disubstituted dopamines.,  21  (3): [PMID:564406] [10.1021/jm00201a002]

9. Ellen Van Damme.  (2021)  Screening of ~5500 FDA-approved drugs and clinical candidates for anti-SARS-CoV-2 activity,  [10.6019/CHEMBL4651402]

Source

Source(3):

• Scientific Literature
• PubChem BioAssays
• IMI-CARE SARS-CoV-2 Data